Abstract
Macular amyloidosis (MA) and lichen amyloidosis (LA) are the two major variants of the primary cutaneous amyloidoses. It is generally accepted that, in both situations, amyloid occurs mainly as a result of keratinocyte degeneration, and there is no relation with systemic amyloidosis. Lesions of the disease are characterized by pigmented macules with a reticulate or rippled appearance in MA, and numerous brownish lichenoid papules in LA that may sometimes be distributed over wide areas of the body. The evolutionary stage between MA and LA is called biphasic amyloidosis (BA). 1 Severe and therapy-resistant pruritus is the most prominent feature and leads to further amyloid deposition by means of frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and beneficial effect has been observed with topical dimethyl sulfoxide (DMSO) therapy. [2] [3] [4] [5] In a previous study, we achieved marked clinical improvement in nine of 10 patients with a 50% solution of DMSO in water in a daily treatment regimen at the end of 6-20 weeks of treatment, but relapses occurred in the post-treatment follow-up period. 6 Histologic examination after the treatment revealed no disappearance of amyloid deposits. Interestingly, pruritus did not recur at least 2 weeks after the cessation of therapy. Therefore, we planned to change the treatment protocol from daily application to intermittent use of DMSO immediately after the disappearance of pruritus. The aims of this study are to investigate whether the patients would benefit from interval therapy and to determine the optimal application interval of DMSO to maintain the relief of symptoms.
Patients and methods
Thirteen patients (11 women and 2 men), who were seen in our outpatient clinic between 1995 and 1997 and were diagnosed as MA, LA, or BA, were enrolled in the study. The clinical diagnosis of amyloidosis was confirmed by histopathologic examination of punch biopsy material stained by hematoxylin and eosin, crystal violet, and Congo-red. The duration of the disease, previous treatments, and their efficacy were recorded. All cases were evaluated with regard to other dermatoses and/or systemic diseases that might cause local or systemic pruritus. This screening was carried out by a detailed physical and dermatologic examination and laboratory tests, including a routine biochemistry panel, thyroid function tests, complete blood count, immunoglobulin E (IgE), chest X-ray, stool examination for parasites, and urine analysis.
All women were evaluated with regard to pregnancy before treatment, and were encouraged to use birth control during treatment. Pregnant or lactating women and patients less than 18 years of age were excluded. Patients were asked not to take any antihistamines or nonsteroidal anti-inflammatory drugs and not to use topical or systemic corticosteroids at least 3 weeks before and during treatment. Before treatment, patients were evaluated with a scoring system for papules and pigmentation on a scale from 0 to 3 (0, absent; 1, mild; 2, moderate; 3, severe). Pruritus as a subjective symptom was graded by patients individually on a 10-cm visual analog scale (0-10).
After written consent, patients were instructed to apply 5-15 mL of DMSO solution with a cotton gauze to their lesional skin after these regions had been cleansed with soap and rinsed with tap water. They were treated once daily with a 50% DMSO solution in water (DMSO zur Synthese Merck Art. No: 802912). When no decrease of pruritus occurred within 2 weeks, treatment was continued with 100% DMSO solution. After the disappearance of pruritus (end score for pruritus fell to 0-1), DMSO was applied at increasing intervals until the widest effective application interval for the maintenance of relief was reached.
Results
The ages of the 13 cases (11 women and 2 men) ranged from 25 to 61 years (mean, 43.8 years) ( Table 1 ). The duration of their disease ranged from 5 to 20 years (mean, 9.9 years). MA was diagnosed in five, LA in two, and BA in six cases. All cases were detected to have a Fitzpatrick skin type of III. None of the cases had a family history of a similar skin eruption. They had not benefited from previous treatments with systemic antihistamines and/or topical corticosteroids. Thyroid disease was detected in one case. Other systemic diseases or dermatoses that may cause pruritus were not detected in any of the patients. Nylon brush, rough towels, and hot showers were the most preferred items used to relieve pruritus. Warm weather, high humidity, and sweating were the main triggering factors for pruritus.
The pre-and post-treatment scores for pruritus, pigmentation, and papules are presented in Table 2 . In all cases, a decrease in the severity of pruritus was observed within 3-7 days of starting DMSO treatment. Pruritus did not disappear in two cases with LA and MA within 4 and 8 weeks of therapy, respectively. In the remaining 11 cases, pruritus disappeared completely after an average therapy period of 4.1 weeks. The mean time required for the remarkable flattening of the papules (defined as a 50% decrease in the pretreatment scores) was 9 weeks. A 50% decrease or more of the pigmentation was achieved in six cases after an average therapy period of 11.6 weeks. After a mean therapy period of 6.5 months, a 47% decrease in pigmentation and 72% flattening of the papules were reached (Figs 1-3) . Nine patients completed the study. The widest effective DMSO application interval achieved in these cases ranged from 3 to 15 days (mean, 8.6 days).
No systemic side-effects or laboratory abnormalities were seen during the treatment period. Transitory local sideeffects were burning and contact urticaria. The burning sensation, that appeared immediately after the application of the DMSO solution and disappeared within the next 20-30 min, showed a decrease in intensity during treatment and lasted only 1-2 min after a few weeks of therapy. Contact urticaria experienced by seven cases at the beginning of treatment was more prominent in cases who used a 100% concentration of DMSO, but disappeared after 3-20 days of therapy. Local dryness and desquamation on the application sites occurred within the first days of treatment and lasted throughout the therapy. They were more prominent in cases treated with the higher concentration of DMSO. All cases experienced a garlic-like breath odor during the treatment period. Two cases gave up BO, breath odor; Patients 6 and 9 gave up therapy due to the unpleasant breath odor.
treatment because of this odor, but other cases became less disturbed by it in the interval treatment period. Control biopsies revealed no disappearance of amyloid deposits. Cases with remarkable flattening of the papular lesions showed a relative decrease in epidermal acanthosis and hyperkeratosis.
Discussion
Recurrent scratching is believed to play a major role in the common etiopathogenesis of MA and LA, 7, 8 perhaps on an unidentified genetic basis. Frictional trauma associated with persistent scratching and rubbing of the same pruritic skin site causes inflammation and leads to the degeneration of keratinocytes. 9 Degenerated keratinocytes drop to the upper portion of the dermis, where the destruction of their tonofilaments results in the formation of amyloid material with a filamentous structure. 9, 10 Indicating the origin, it is called amyloid-K. 11 Persistent friction may also be responsible for the pigmentation of the lesions by the mechanical stimulation of melanocytes. 12 Persistent scratching of the skin leads to additional epidermal changes, such as hyperk- eratosis and acanthosis with the formation of papules. As a result, MA may change to LA via BA. 9, 12 Because the amyloid material is very hard to dissolve, efforts regarding the treatment of MA and LA have usually resulted in failure. Variable success has been obtained with various therapeutic modalities, such as intralesional corticosteroids, dermabrasion, 13 UVB, 14 etretinate, 15, 16 and cyclophosphamide. 17 Recently, in a few case reports, authors have observed encouraging beneficial clinical effects by using topical DMSO. [2] [3] [4] [5] DMSO is an odorless, colorless, hygroscopic liquid chemical and is a strong solvent for organic and inorganic substances. 18 These features provide a wide range of pharmacologic effects. Most important are the enhancing effect of membrane penetration and anti-inflammatory, cryoprotective, analgesic, weak bacteriostatic, diuretic, mast-celldepleting, histamine-liberating, vasodilatory, collagen-dissolving, and OH-binding antioxidant effects. 18 It is well absorbed and excreted in large quantities by the kidneys. A small amount is metabolized to dimethyl sulfide and excreted through the lungs and skin, resulting in a garliclike odor from the patients. 19 This odor may sometimes be so intense as to disturb the patient causing him/her to give up the treatment. In this study, two cases (15%) gave up therapy because of the breath odor.
In various diseases, DMSO is used topically or by the oral, intravenous, and intravesical route mainly for its antiinflammatory, local analgesic, diuretic, and antioxidant effects. 18, 19 Toxicities reported include nausea, vomiting, cramps, and chills in humans, and corneal opacities in experimental animals followed topical use. 18, 20 Although the oral administration of DMSO has been reported to be promising in some metabolic diseases, such as systemic amyloidosis, 21 lipoid proteinosis, 22 and scleromyxedema, 23 which are characterized by the deposition of amyloid, collagen, hyaline, or mucopolysaccharide in the skin, there is still not enough evidence that DMSO is able to dissolve these substances.
The topical use of DMSO in cutaneous amyloidosis has been studied in only a limited number of cases. Highly successful results were obtained in MA and LA cases over a short treatment period with concentrations between 10% and 100%. [2] [3] [4] [5] Pruritus disappeared within a week and remarkable flattening of the papular lesions was achieved in 2-16 weeks of therapy. Interestingly, histopathologic examinations revealed no decrease in amyloid deposits. In a previous study, we also achieved good clinical results in 90% of cases with a 50% concentration of DMSO. 6 The rapid clinical improvement, in contrast with the persistence of amyloid deposits in the histopathologic sections, could not be explained by a possible amyloid-dissolving effect. In an in vitro study by Lim et al., 24 no decrease in amyloid deposits could be obtained in the Congo-red-stained histo-pathologic sections of punch biopsy material from an LA patient when incubated with pure DMSO for 3, 5, and 7 days. The clinical improvement, as suggested by Harman, 25 may partially be related to the OH-radical-binding capacity of DMSO that results in a decrease in the formation of new amyloid fibrils, thus relieving their pressure effect on the nerve endings. Mast cell depletion by DMSO may be another probable explanation for the rapid improvement of pruritus, although a relationship between amyloid and mast cells is not known, and antihistamines usually fail to improve the amyloid-related pruritus. Another possible explanation may be the nerve blockade by DMSO, 19 or by the mediators released from the mast cells. These may inhibit the synaptic transmission of type C nerve endings, either directly or via stimulation of type A nerves (the so-called gate-control-system 26 ). Although speculative, a capsaicin-like substance P depletion effect from the nerve endings by DMSO would explain the rapid improvement of pruritus. Pruritus would not recur until the substance P granules were refilled, thus making the intermittent use of DMSO possible.
We believe that the improvement of the papular lesions, consistent with a relative decrease in hyperkeratosis and acanthosis, is closely related to the disappearance of pruritus and scratching. A direct effect of DMSO on the epidermis, causing a decrease in hyperkeratosis and acanthosis, is not known. 27 In the follow-up period of our previous study, relapses of pruritus were observed in an average of 3.3 weeks. In this study, we observed that pruritus did not recur when DMSO was applied at an average interval of 9 days. The difference can be explained by the fact that, in the previous study, patients were only noted as having recurrence when pruritus was intractable, whereas, in this study, even the mildest sensation of pruritus was recorded. Remarkable flattening of the papular lesions was obtained within 11 weeks in the previous study and within 9 weeks in this study. This finding suggests that it is not the frequency of DMSO application, but the disappearance of pruritus and the related scratching effect, that are crucial for improvement.
Conclusions
Locally applied DMSO can break the vicious ''pruritusamyloid deposition-pruritus'' cycle in patients with MA, LA, and BA. In addition to its daily use, interval therapy seems to maintain this effect, enabling the patients to tolerate the side-effects more easily. According to these clinical observations, the characteristics of amyloid pruritus need further evaluation. The possible roles of type C nerves, inflammatory cells, and mediators, including cytokines, in cutaneous amyloidosis are awaiting further investigation.
